CLARENCE, N.Y - Wednesday, September 18th 2013 [ME NewsWire]
(BUSINESS
WIRE) 22nd Century Group, Inc. (OTCQB: XXII) announced that the
company and NASCO Products, LLC entered into a definitive and binding
agreement for 22nd Century Group to purchase NASCO Products. NASCO
Products, a federally licensed tobacco product manufacturer, is also a
participating member of the Tobacco Master Settlement Agreement known as
the MSA, an agreement among 46 U.S. states and the tobacco industry
administered by the National Association of Attorneys General (NAAG).
The
purchase price for the NASCO acquisition is $1 million payable in a
combination of cash and equity. The purchase agreement also contemplates
that 22nd Century will enter into a management agreement and a sales
agreement at closing with an affiliate of NASCO Products. In addition,
22nd Century will purchase cigarette manufacturing machinery for
approximately $2 million.
Upon closing, which will take place
immediately following NAAG’s consent of the acquisition, NASCO Products,
LLC will become a wholly-owned manufacturing subsidiary of 22nd Century
Group. Current president of NASCO Products, Ralph Angiuoli, will be
part of the management team of the new 22nd Century Group subsidiary.
Mr. Angiuoli, former President and CEO of RJ Reynolds Tobacco Company,
is a 30-year veteran of the industry.
Barry Saintsing and Ralph
Angiuoli Jr., owners of an affiliate of NASCO Products, will also join
the 22nd Century management team. Mr. Saintsing was formerly with RJ
Reynolds Tobacco Company for 34 years and retired as Master Product
Developer. Mr. Angiuoli, Jr. was also formerly with RJ Reynolds as a
sales and marketing representative. Joseph Pandolfino, CEO of 22nd
Century Group, explained, “Having the NASCO Products team aboard will be
of tremendous benefit to 22nd Century Group by facilitating the
production and distribution of our products in the United States.”
Goodrich
Tobacco Company, the distribution arm of 22nd Century Group, has thus
far utilized contract manufacturers that are not members of the MSA to
produce the company’s cigarette brands. Henry Sicignano, President of
Goodrich Tobacco, explained, “We intentionally have delayed expansion of
the marketing and distribution of our brands in the United States since
the more product we sold, the more difficult and expensive it would be
to become a participating manufacturer of the MSA. 22nd Century Group
owning NASCO Products resolves this issue.” Upon NAAG’s consent of the
acquisition, 22nd Century will move forward with widespread distribution
and sales of the company’s brands throughout the United States.
Mr.
Sicignano added, “We look forward to obtaining consent of NAAG for the
NASCO Products acquisition so that our super-premium brands, RED SUN and
MAGIC can be sold under the MSA.”
22nd Century also produces a
research cigarette, SPECTRUM, for the U.S. government that is
distributed under the direction of NIDA, a component of the U.S.
National Institutes of Health. The SPECTRUM product line includes a
series of cigarette styles that have a similar “tar” yield but varying
nicotine yields over a 50-fold range – from very low to high – due to
different levels of nicotine in the tobacco. No other company in the
world is capable of producing cigarettes with such a wide range of
nicotine content. SPECTRUM is not a commercial cigarette but is strictly
for research purposes. 22nd Century has delivered approximately 12
million SPECTRUM cigarettes and has recently received a purchase order
for another 5.5 million SPECTRUM cigarettes which equates to 275,000
packs of 20.
About 22nd Century Group, Inc.
22nd Century
is a plant biotechnology company whose proprietary technology allows for
the levels of nicotine and other nicotinic alkaloids (e.g.,
nornicotine, anatabine and anabasine) in the tobacco plant to be
decreased or increased through genetic engineering or plant breeding.
22nd Century owns or is the exclusive licensee of 112 issued patents in
78 countries plus an additional 38 pending patent applications. Goodrich
Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned
subsidiaries of 22nd Century. Goodrich Tobacco is focused on commercial
tobacco products and tobacco harm reduction products in development.
Hercules Pharmaceuticals is focused on X-22, a prescription smoking
cessation aid in development.
For additional information, please visit: www.xxiicentury.com
Cautionary
Note Regarding Forward-Looking Statements: This press release contains
forward-looking information, including all statements that are not
statements of historical fact regarding the intent, belief or current
expectations of 22nd Century Group, Inc., its directors or its officers
with respect to the contents of this press release. The words “may,”
“would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend”
and similar expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results, levels
of activity or performance. You should not place undue reliance on these
forward-looking statements, which speak only as of the date that they
were made. These cautionary statements should be considered with any
written or oral forward-looking statements that we may issue in the
future. Except as required by applicable law, including the securities
laws of the United States, we do not intend to update any of the
forward-looking statements to conform these statements to reflect actual
results, later events or circumstances or to reflect the occurrence of
unanticipated events. You should carefully review and consider the
various disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2012, filed on March 18, 2013, including
the section entitled “Risk Factors,” and our other reports filed with
the U.S. Securities and Exchange Commission which attempt to advise
interested parties of the risks and factors that may affect our
business, financial condition, results of operation and cash flows. If
one or more of these risks or uncertainties materialize, or if the
underlying assumptions prove incorrect, our actual results may vary
materially from those expected or projected.
Contacts
Redington, Inc.
Tom Redington, 203-222-7399

No comments:
Post a Comment